Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis
Journal
Hemodialysis international. International Symposium on Home Hemodialysis
Journal Volume
26
Journal Issue
3
Pages
369
Date Issued
2022
Author(s)
Tung, Kuei-Ting
Peng, Yu-Sen
Hsu, Shih-Ping
Wu, Hon-Yen
Chiu, Yen-Ling
Yang, Ju-Yeh
Pai, Mei-Fen
Shu, Kai-Hsiang
Lu, Hui-Ming
Liao, Chun-Hsing
Chu, Fang-Yeh
Tsai, Wan-Chuan
Abstract
The immunogenicity of vaccines is known to be attenuated in patients with end-stage kidney disease due to uremia. Patients on dialysis were excluded from coronavirus disease 2019 (COVID-19) vaccine trials; thus, the effectiveness of vaccines for this population is unclear. The aim of this study was to explore whether Asian dialysis patients can effectively produce an immune response after being vaccinated with the first dose of the ChAdOx1 nCoV-19 vaccine.
Subjects
Asian; COVID-19; ChAdOx1 nCoV-19 vaccine; dialysis; humoral response; seropositive
SDGs
Publisher
WILEY
Type
journal article